[7] Pratt EH, Stokes JW, Fan E. Bleeding and clotting while supported with ECMO: time to move forward[J]. Intensive Care Med, 2022,48(8):1059-1061. [8] Uchiba M, Okajima K, Abe H, et al. Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor Ⅶa...
Conclusion Combination therapy with nafamostat and heparin can prevent circuit thrombosis during ECMO. However, bleeding can still develop with this combination therapy during ECMO.doi:10.1002/ams2.585John Wiley & Sons, LtdAcute Medicine & Surgery...
Nafamostat mesilate, a synthetic serine protease inhibitor, has seen increased use as a substitute for heparin in patients undergoing ECMO ... JY Lim,JB Kim,SJ Choo,... - 《Annals of Thoracic Surgery》 被引量: 7发表: 2016年 Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat ...
Heparin (n = 51) 30 (52.9) 12 (23.5) 9 (17.6) 42 12 (29) 13 (31) 8 (19) 6 =-=(14)-=- 1 (2) 2 (5) P value 0.048 The number of cases in which ECMO is used to treat cardiopulmonary failure is increasing. Although the incidence of bleeding complications has decreased in ...
Nafamostat mesylate may be effective against coronavirus disease 2019 (COVID-19). However, it is not known whether its use is associated with reduced in-hospital mortality in clinical practice. We conducted a retrospective observational study to evaluate